Vijay Pande
June 10, 2025 08:38 AM EDT
People

For­mer a16z biotech in­vest­ment leader Vi­jay Pande ex­its the VC firm

Kyle LaHucik

Biotech Correspondent

Vi­jay Pande is leav­ing An­dreessen Horowitz af­ter 11 years at the VC firm, he wrote in Mon­day evening posts on LinkedIn …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

Broad In­sti­tute con­ducts lay­offs as it preps for cuts in fed­er­al fund­ing; Dyne’s fi­nanc­ing

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

A service from the Financial Times